Tempus AI Raises $400M and Expands Beyond Oncology With Alzheimer's Blood Test Collaboration 🔗

Tempus AI raised $400 million through a convertible note offering and announced a new collaboration with Lucent Diagnostics to expand access to Alzheimer's blood biomarker testing. The Lucent partnership uses Tempus's existing clinical data infrastructure to identify patients eligible for the recently FDA-cleared blood-based Alzheimer's tests, integrating the diagnostic workflow with Tempus's broader precision medicine platform. The combined moves mark Tempus's first meaningful expansion outside oncology — the company has built its commercial base on molecular profiling for cancer — and signal a deliberate widening of its diagnostic footprint. The capital raise gives Tempus runway to fund that expansion without near-term reliance on equity markets. For a company whose Q1 losses widened to $0.70 EPS, the financing decision matters as much as the strategic one.

Sanofi Commits $294M to Expand Its Toronto AI Center of Excellence 🔗

Sanofi will invest $294 million over five years to expand its AI Center of Excellence in Toronto, scaling the hub it established in 2021 into one of the company's primary digital innovation sites. The expansion adds capabilities across drug discovery, manufacturing, and patient services, and is positioned as part of Sanofi's company-wide AI strategy rather than a regional play. The investment continues a pattern that has defined the past six weeks of newsletter coverage: pharma capital flowing into dedicated AI infrastructure at hundreds of millions per site. Boehringer Ingelheim committed £150 million to a London AI centre last month. Roche activated 3,500 NVIDIA Blackwell GPUs across its US and European sites in March. The infrastructure layer of pharma AI is now being built in concrete, not slides.

Doceree Launches Daily Command — A New $30B Software Category for Pharma Brand Teams 🔗

At its Health Decode Summit on May 7, Doceree launched Daily Command, an operating system for pharmaceutical brand teams co-built with 75 senior operators from companies including Sanofi and Merck, and 18 of the most senior agency leaders in pharma marketing. The pitch is framed as pharma's "Workday moment": consolidating the fragmented $30 billion annual pharma marketing software market into a single platform that integrates planning, execution, and measurement. The claim is large and will be tested by the market, but the pre-commitment of 75 senior operators and 18 agency leaders at launch is a different category of validation than a typical product release. If Daily Command holds even part of the category it claims, the implications for existing point-solution vendors in pharma marketing — content management, sales enablement, omnichannel orchestration — are significant.

Modicus Prime Raises $8M for AI Audit Readiness — The Compliance Category Keeps Maturing 🔗
Modicus Prime closed an $8 million round to expand its AI audit readiness platform for pharma. The product focuses on a narrow but increasingly critical problem: continuously validating that AI systems deployed in GxP-regulated environments meet documentation, traceability, and inspection-readiness requirements at the moment a regulator asks for them. The round joins Iridius's $8.6 million seed (covered last month) and i-GENTIC AI's GENIE platform expansion as part of a now-clear cluster of capital flowing into AI compliance infrastructure.

The signal: Three funded companies, one consistent thesis: AI in pharma cannot ship without an audit layer beneath it. The buyers are the same buyers Pistoia's data identifies as getting the most value from AI — regulatory and quality teams. The compliance category is no longer an adjacency to AI in pharma; it is becoming a precondition. Expect more capital here, and expect the pharma platform vendors (Veeva, IQVIA, Medidata) to either acquire or build equivalents within 12 months.

Snowflake and Veeva Connect the Data Cloud to Vault. Agentic AI Gets Its Pipes 🔗

Snowflake and Veeva announced a partnership to connect the Snowflake AI Data Cloud directly to Veeva Vault through a new Openflow Connector. The integration enables life sciences organisations to run analytics and agentic AI workflows on read-only Vault data — across clinical, regulatory, quality, and safety domains — without exporting it out of governed environments. Compliance controls remain at the Vault layer; analytics and agent execution happen in Snowflake's compute environment.

The signal: Two months ago, Veeva acquired Ostro to absorb the compliant conversational AI layer for pharma. This week, it formalises the data pipe needed to run agentic AI workflows on top of its own platform. The two moves together describe a coherent strategy: Veeva is positioning Vault as the system of record under which agentic AI executes in regulated life sciences. The pipes are being laid. The vendors competing for that orchestration layer — Domino Data Lab, Databricks, the cloud hyperscalers — are now operating in a market where the dominant pharma data platform has chosen its partner for the agent-execution layer. The structural decision has been made.

BC Platforms and AWS Sign a Strategic Collaboration Agreement — Genomic Data Joins the Cloud Layer 🔗

BC Platforms signed a Strategic Collaboration Agreement with AWS to scale its BC Mosaic platform on AWS infrastructure. BC Mosaic is a federated healthcare data activation platform connecting over 150 data partners covering more than 187 million patient lives across 35 countries, with NVIDIA RAPIDS integrated for computational analysis. The collaboration includes joint marketing, AWS Marketplace integration, and is positioned to support European Health Data Space compliance for cross-border clinical and genomic research.

The signal: Two months ago the genomic and real-world data layer of pharma was still fragmented across regional players and bespoke data partnerships. This week, one of the largest genomic data platforms outside the US chose AWS as its scale-up partner — formally, with joint marketing and a marketplace listing. Combined with last month's Snowflake/Veeva announcement and AWS's own European Sovereign Cloud push, the picture sharpens: the genomic and clinical data layer of pharma AI is being assembled on a small number of cloud platforms, with regional compliance as the orchestration constraint. The independent genomic data startup raising on a "we'll be your data platform" pitch is now competing against fully cloud-integrated alternatives.